Cantor analyst Mara Goldstein came out today with a bullish note on shares of Celgene Corporation (NASDAQ:CELG), after the pharma giant pre-announced 2016 results …
Celgene Corporation (NASDAQ:CELG) presented at JPM this morning, providing guidance updates and top-line FY2016 results. While FY2016 top-line results were slightly below expectations, …
Celgene Corporation (NASDAQ:CELG) provided a business update as well as its preliminary 2016 unaudited results and financial guidance for 2017 at the 35th …
Celgene Corporation (NASDAQ: CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending …
Oppenheimer analyst Leah R. Cann has reiterated her Buy rating for Celgene Corporation (NASDAQ: CELG) after the firm’s pipeline drug Otezla has now become …
Juno Therapeutics Inc (NASDAQ:JUNO) and Celgene Corporation (NASDAQ:CELG) announced that the U.S.
Celgene Corporation (NASDAQ:CELG) announced that OTEZLA (apremilast), Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing authorization by Japan’s Ministry …
Celgene Corporation (NASDAQ:CELG) announced that the results of its randomized phase II tnAcity trial of ABRAXANE for injectable suspension (paclitaxel protein-bound particles for injectable …
Celgene Corporation (NASDAQ:CELG) announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) …
In a research report released Monday, Cantor analyst Mara Goldstein reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price …
